IMMUNOINFLAMMATORY RHEUMATIC DISEASES ASSOCIATED WITH TYPE I INTERFERON: NEW EVIDENCE
https://doi.org/10.14412/1995-4484-2019-452-461
Abstract
Immunoinflammatory rheumatic diseases (IIRDs) are a large group of pathological conditions with impaired immunological tolerance to autogenous tissues, leading to inflammation and irreversible organ damage. The review discusses current ideas on the role of type I interferons in the immunopathogenesis of IIRDs, primarily systemic lupus erythematosus, and new possibilities for personalized therapy.
About the Authors
E. L. Nasonov
V.A. Nasonova Research Institute of Rheumatology;
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
8, Trubetskaya St., Build. 2, Moscow 119991
A. S. Avdeeva
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
References
1. Sanayama Y, Ikeda K, Saito Y, et al. Prediction of therapeutic responses to tocilizumab in patients with rheumatoid arthritis: biomarkers identified by analysis of gene expression in peripheral blood mononuclear cells using genome-wide DNA microarray. Arthritis Rheum. 2014;66(6):1421-31. doi: 10.1002/art.38400
2. Bodewes ILA, Al-Ali S, van Helden-Meeuwsen CG, et al. Systemic interferon type I and type II signatures in primary Sjö gren's syndrome reveal differences in biological disease activity. Rheumatology. 2018;57:921-30. doi: 10.1093/rheumatology/kex490
3. Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol. 2014;14:36-49. doi: 10.1038/nri3581
4. Nasonov EL, Aleksandrova EN, Novikov AA. Autoimmune rheumatic diseases – problems of immunopathology and personalized therapy. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk. 2015;70(2):169-82 (In Russ.).
5. Mavragani CP, La DT, Stohl W, Crow MK. Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-β/α ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort. Arthritis Rheum. 2010;62:392-401. doi: 10.1002/art.27226
6. Dieude P, Guedj M, Wipff J, et al. STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis. Arthritis Rheum. 2009;60:2472-9. doi: 10.1002/art.24688
7. Crow YJ. Type I interferonopathies: a novel set of inborn errors of immunity: type I interferonopathies. Ann N Y Acad Sci Nov. 2011;1238:91-8. doi: 10.1111/j.1749-6632.2011.06220.x
8. Wang L, Wang F-S, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015;278:369-95. doi: 10.1111/joim.12395
9. Wampler Muskardin T, Vashisht P, Dorschner JM, et al. Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritis. Ann Rheum Dis. 2016;75(10):1757-62. doi: 10.1136/annrheumdis-2015-208001
10. Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 2000;43:1431-42. doi: 10.1002/1529-0131(200007)43:7<1431::AID-ANR3>3.0.CO;2-E
11. Rö nnblom L, Eloranta M-L. The interferon signature in autoimmune diseases. Curr Opin Rheumatol. 2013;25:248-53. doi: 10.1097/BOR.0b013e32835c7e32
12. Gourh P, Agarwal SK, Divecha D, et al. Polymorphisms in TBX21 and STAT4 increase the risk of systemic sclerosis: evidence of possible gene-gene interaction and alterations in Th1/Th2 cytokines. Arthritis Rheum. 2009;60:3794-806. doi: 10.1002/art.24958
13. De Jong TD, Blits M, de Ridder S, et al. Type I interferon response gene expression in established rheumatoid arthritis is not associated with clinical parameters. Arthritis Res Ther. 2016;18:Article number 290. doi: 10.1186/s13075-016-1191-y
14. Picard C, Belot A. Does type-I interferon drive systemic autoimmunity? Autoimmun Rev. 2017;16(9):897-902. doi: 10.1016/j.autrev.2017.07.001
15. Rueda B, Broen J, Simeon C, et al. The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype. Hum Mol Genet. 2009;18:2071-7. doi: 10.1093/hmg/ddp119
16. Kretschmer S, Lee-Kirsch MA. Type I interferon-mediated autoinflammation and autoimmunity. Curr Opin Immunol. 2017;49:96-102. doi: 10.1016/j.coi.2017.09.003
17. De Jong TD, Vosslamber S, Blits M, et al. Effect of prednisone on type I interferon signature in rheumatoid arthritis: consequences for response prediction to rituximab. Arthritis Res Ther. 2015;17:78. doi: 10.1186/s13075-015-0564-y
18. Skaug B, Assassi S. Type I interferon dysregulation in Systemic Sclerosis. Cytokine. 2019 Jan 23. doi: 10.1016/j.cyto.2018.12.018
19. Green DS, Young HA, Valencia JC. Current prospects of type II interferon γ signaling and autoimmunity. J Biol Chem. 2017;25;292(34):13925-33. doi: 10.1074/jbc.R116.774745
20. Higgs BW, Liu Z, White B, et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis. 2011;70:2029-36. doi: 10.1136/ard.2011.150326
21. De Jong TD, Snoek T, Mantel E, et al. Dynamics of the Type I Interferon Response During Immunosuppressive Therapy in Rheumatoid Arthritis. Front Immunol. 2019 Apr 24;10:902. doi: 10.3389/fimmu.2019.00902
22. Psarras A, Emery P, Vital EM. Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy. Rheumatology (Oxford). 2017;56(10):1662-75. doi: 10.1093/rheumatology/kew431
23. Christmann RB, Sampaio-Barros P, Stifano G, et al. Association of interferon- and transforming growth factor β-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis. Arthritis Rheum. 2014;66:714-25. doi: 10.1002/art.38288
24. Chasset F, Arnaud L. Targeting interferons and their pathways in systemic lupus erythematosus. Autoimmun Rev. 2018;17:44-52. doi: 10.1016/j.autrev.2017.11.009
25. Thorlacius GE, Wahren-Herlenius M, Ronnblom L. An update on the role of type I interferons in systemic lupus erythematosus and Sjogren's syndrome. Curr Opin Rheumatol. 2018;30:471-81. doi: 10.1097/BOR.0000000000000524
26. Muskardin TLW, Niewold TB. Type I interferon in rheumatic diseases. Nat Rev Rheumatol. 2018;14(4):214-28. doi: 10.1038/nrrheum.2018.31
27. George PM, Oliver E, Dorfmuller P, et al. Evidence for the involvement of type I interferon in pulmonary arterial hypertension. Circ Res. 2014;114:677-88. doi: 10.1161/CIRCRESAHA.114.302221
28. Crow MK, Olferiev M, Kirou KA. Type I Interferons in Autoimmune Disease. Annu Rev Pathol. 2019;14:369-93. doi: 10.1146/annurev-pathol-020117-043952
29. Nezos A, Gravani F, Tassidou A, et al. Type I and II interferon signatures in Sjogren's syndrome pathogenesis: contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis. J Autoimmun. 2015;63:47-58. doi: 10.1016/j.jaut.2015.07.002
30. Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol. 2014;32:513-45. doi: 10.1146/annurev-immunol-032713-120231
31. Garcia-Romo GS, Caielli S, Vega B, et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med. 2011;3:ra20. doi: 10.1126/scitranslmed.3001201
32. Brkic Z, van Bon L, Cossu M, et al. The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis. Ann Rheum Dis. 2016;75(8):1567-73. doi: 10.1136/annrheumdis-2015-207
33. Benchabane S, Belkhelfa M, Belguendouz H, et al. Interferon-γ inhibits inflammatory responses mediators via suppression of iNOS signaling pathway in PBMCs from patients with primary Sjö gren's syndrome. Inflammopharmacology. 2018;26:1165-74. doi: 10.1007/s10787-018-0499-4
34. Banchereau R, Cepika AM, Banchereau J, Pascual V. Understanding Human Autoimmunity and Autoinflammation Through Transcriptomics. Annu Rev Immunol. 2017;35:337-70. doi: 10.1146/annurev-immunol-051116-052225
35. Doedens JR, Jones WD, Hill K, et al. Blood-borne Rna correlates with disease activity and Ifn-stimulated gene expression in systemic lupus erythematosus. J Immunol. 2016;197:2854-63. doi: 10.4049/jimmunol.1601142
36. Van den Hoogen LL, Fritsch-Stork RD, Versnel MA, et al. Monocyte type I interferon signature in antiphospholipid syndrome is related to proinflammatory monocyte subsets, hydroxychloroquine and statin use. Ann Rheum Dis. 2016;75:e81. doi: 10.1136/annrheumdis-2016-210485
37. Bodewes ILA, Al-Ali S, van Helden-Meeuwsen CG, et al. Systemic interferon type I and type II signatures in primary Sjö gren's syndrome reveal differences in biological disease activity. Rheumatology. 2018;57:921-30. doi: 10.1093/rheumatology/kex490
38. Mavragani CP, Sagalovskiy I, Guo Q, et al. Expression of long interspersed nuclear element 1 retroelements and induction of type I interferon in patients with systemic autoimmune disease. Arthritis Rheum. 2016;68:2686-96. doi: 10.1002/art.39795
39. Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol. 2014;14:36-49. doi: 10.1038/nri3581
40. Ugolini-Lopes MR, Torrezan GT, Gandara APR, et al. Enhanced type I interferon gene signature in primary antiphospholipid syndrome: Association with earlier disease onset and preeclampsia. Autoimmun Rev. 2019;18(4):393-8. doi: 10.1016/j.autrev.2018.11.004
41. Dieude P, Guedj M, Wipff J, et al. STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis. Arthritis Rheum. 2009;60:2472-9. doi: 10.1002/art.24688
42. Crow YJ. Type I interferonopathies: a novel set of inborn errors of immunity: type I interferonopathies. Ann N Y Acad Sci Nov. 2011;1238:91-8. doi: 10.1111/j.1749-6632.2011.06220.x
43. Lee JY, Park JK, Lee EY, et al. Circulating exosomes from patients with systemic lupus erythematosus induce an proinflammatory immune response. Arthritis Res Ther. 2016;18:264. doi: 10.1186/s13075-016-1159-y
44. Palli E, Kravvariti E, Tektonidou MG. Type I Interferon Signature in Primary Antiphospholipid Syndrome: Clinical and Laboratory Associations. Front Immunol. 2019;10:487. doi: 10.3389/fimmu.2019.00487
45. Gourh P, Agarwal SK, Divecha D, et al. Polymorphisms in TBX21 and STAT4 increase the risk of systemic sclerosis: evidence of possible gene-gene interaction and alterations in Th1/Th2 cytokines. Arthritis Rheum. 2009;60:3794-806. doi: 10.1002/art.24958
46. Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 2000;43:1431-42. doi: 10.1002/1529-0131(200007)43:7<1431::AID-ANR3>3.0.CO;2-E
47. Grenn RC, Yalavarthi S, Gandhi AA, et al. Endothelial progenitor dysfunction associates with a type I interferon signature in primary antiphospholipid syndrome. Ann Rheum Dis. 2017;76:450-7. doi: 10.1136/annrheumdis-2016-209442
48. Bengtsson AA, Rö nnblom L. Role of interferons in SLE. Best Pract Res Clin Rheumatol. 2017;31(3):415-28. doi: 10.1016/j.berh.2017.10.0
49. Rueda B, Broen J, Simeon C, et al. The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype. Hum Mol Genet. 2009;18:2071-7. doi: 10.1093/hmg/ddp119
50. Eloranta ML, Rö nnblom L. Cause and consequences of the activated type I interferon system in SLE. J Mol Med (Berl). 2016;94(10):1103-10. doi: 10.1007/s00109-016-1421-4
51. Greenberg SA, Pinkus JL, Pinkus GS, et al. Interferon-β/α-mediated innate immune mechanisms in dermatomyositis. Ann Neurol. 2005;57:664-78. doi: 10.1002/ana.20464
52. Picard C, Belot A. Does type-I interferon drive systemic autoimmunity? Autoimmun Rev. 2017;16(9):897-902. doi: 10.1016/j.autrev.2017.07.001
53. Skaug B, Assassi S. Type I interferon dysregulation in Systemic Sclerosis. Cytokine. 2019 Jan 23. doi: 10.1016/j.cyto.2018.12.018
54. Liao AP, Salajegheh M, Nazareno R, et al. Interferon β is associated with type 1 interferon-inducible gene expression in dermatomyositis. Ann Rheum Dis. 2011;70:831-6. doi: 10.1136/ard.2010.139949
55. Higgs BW, Liu Z, White B, et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis. 2011;70:2029-36. doi: 10.1136/ard.2011.150326
56. Weckerle CE, Franek BS, Kelly JA, et al. Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosus. Arthritis Rheum. 2011;63(4):1044-53. doi: 10.1002/art.30187
57. Christmann RB, Sampaio-Barros P, Stifano G, et al. Association of interferon- and transforming growth factor β-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis. Arthritis Rheum. 2014;66:714-25. doi: 10.1002/art.38288
58. Chasset F, Arnaud L. Targeting interferons and their pathways in systemic lupus erythematosus. Autoimmun Rev. 2018;17:44-52. doi: 10.1016/j.autrev.2017.11.009
59. Baechler EC, Batliwalla FM, Karypis G, et al. Interferoninducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A. 2003;100(5):2610-5. doi: 10.1073/pnas.0337679100
60. Somani A-K, Swick AR, Cooper KD, et al. Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling. Arch Dermatol. 2008;144:1341-9. doi: 10.1001/archderm.144.10.1341
61. George PM, Oliver E, Dorfmuller P, et al. Evidence for the involvement of type I interferon in pulmonary arterial hypertension. Circ Res. 2014;114:677-88. doi: 10.1161/CIRCRESAHA.114.302221
62. Munroe ME, Lu R, Zhao YD, et al. Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. Ann Rheum Dis. 2016;75(11):2014-21. doi: 10.1136/annrheumdis-2015-2081
63. Crow MK, Olferiev M, Kirou KA. Type I Interferons in Autoimmune Disease. Annu Rev Pathol. 2019;14:369-93. doi: 10.1146/annurev-pathol-020117-043952
64. Piper CJM, Wilkinson MGL, Deakin CT, et al. CD19+CD24hiCD38hi B Cells Are Expanded in Juvenile Dermatomyositis and Exhibit a Pro-Inflammatory Phenotype After Activation Through Toll-Like Receptor 7 and Interferon-α. Front Immunol. 2018;9. doi: 10.3389/fimmu.2018.01372
65. Brkic Z, van Bon L, Cossu M, et al. The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis. Ann Rheum Dis. 2016;75(8):1567-73. doi: 10.1136/annrheumdis-2015-207
66. Niewold TB, Hua J, Lehman TJ, et al. High serum IFN-α activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun. 2007;8:492-502. doi: 10.1038/sj.gene.6364408
67. Garcia-Romo GS, Caielli S, Vega B, et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med. 2011;3:ra20. doi: 10.1126/scitranslmed.3001201
68. Oon S, Wilson NJ, Wicks I. Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway. Clin Transl Immunol. 2016;5:e79. doi: 10.1038/cti.2016.26
69. Van den Hoogen LL, Fritsch-Stork RD, Versnel MA, et al. Monocyte type I interferon signature in antiphospholipid syndrome is related to proinflammatory monocyte subsets, hydroxychloroquine and statin use. Ann Rheum Dis. 2016;75:e81. doi: 10.1136/annrheumdis-2016-210485
70. Kariuki SN, Franek BS, Kumar AA, et al. Trait-stratified genome-wide association study identifies novel and diverse genetic associations with serologic and cytokine phenotypes in systemic lupus erythematosus. Arthritis Res Ther. 2010;12(4):R151. doi: 10.1186/ar3101
71. Doedens JR, Jones WD, Hill K, et al. Blood-borne Rna correlates with disease activity and Ifn-stimulated gene expression in systemic lupus erythematosus. J Immunol. 2016;197:2854-63. doi: 10.4049/jimmunol.1601142
72. Mathian A, Hie M, Cohen-Aubart F, et al. Targeting interferons in systemic lupus erythematosus: current and future prospects. Drugs. 2015;75:835-46. doi: 10.1007/s40265-015-0394-x
73. Md Yusof MY, Psarras A, El-Sherbiny YM, et al. Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status. Ann Rheum Dis. 2018;77:1432-9. doi: 10.1136/annrheumdis-2018-213386
74. Ugolini-Lopes MR, Torrezan GT, Gandara APR, et al. Enhanced type I interferon gene signature in primary antiphospholipid syndrome: Association with earlier disease onset and preeclampsia. Autoimmun Rev. 2019;18(4):393-8. doi: 10.1016/j.autrev.2018.11.004
75. Mavragani CP, Sagalovskiy I, Guo Q, et al. Expression of long interspersed nuclear element 1 retroelements and induction of type I interferon in patients with systemic autoimmune disease. Arthritis Rheum. 2016;68:2686-96. doi: 10.1002/art.39795
76. Bodewes ILA, Gottenberg JE, van Helden-Meeuwsen CG, et al. Hydroxychloroquine treatment downregulates systemic interferon activation in primary Sjö gren's syndrome in the JOQUER randomized trial. Rheumatology (Oxford). 2019 Jun 25. doi: 10.1093/rheumatology/kez242
77. Palli E, Kravvariti E, Tektonidou MG. Type I Interferon Signature in Primary Antiphospholipid Syndrome: Clinical and Laboratory Associations. Front Immunol. 2019;10:487. doi: 10.3389/fimmu.2019.00487
78. Morimoto AM, Flesher DT, Yang J, et al. Association of endogenous anti-interferon-α autoantibodies with decreased interferonpathway and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:2407-15. doi: 10.1002/art.30399
79. Lee JY, Park JK, Lee EY, et al. Circulating exosomes from patients with systemic lupus erythematosus induce an proinflammatory immune response. Arthritis Res Ther. 2016;18:264. doi: 10.1186/s13075-016-1159-y
80. Gardet A, Pellerin A, McCarl CA, et al. Effect of in vivo Hydroxychloroquine and ex vivo Anti-BDCA2 mAb Treatment on pDC IFNγ Production From Patients Affected With Cutaneous Lupus Erythematosus. Front Immunol. 2019;10:275. doi: 10.3389/fimmu.2019.00275
81. Landolt-Marticorena C, Bonventi G, Lubovich A, et al. Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus. Ann Rheum Dis. 2009;68(9):1440-6. doi: 10.1136/ard.2008.093146
82. Grenn RC, Yalavarthi S, Gandhi AA, et al. Endothelial progenitor dysfunction associates with a type I interferon signature in primary antiphospholipid syndrome. Ann Rheum Dis. 2017;76:450-7. doi: 10.1136/annrheumdis-2016-209442
83. Olsen NJ, McAloose C, Carter J, et al. Clinical and Immunologic Profiles in Incomplete Lupus Erythematosus and Improvement with Hydroxychloroquine Treatment. Autoimmune Dis. 2016:8791629. doi: 10.1155/2016/8791629
84. Bengtsson AA, Rö nnblom L. Role of interferons in SLE. Best Pract Res Clin Rheumatol. 2017;31(3):415-28. doi: 10.1016/j.berh.2017.10.0
85. Petri M, Singh S, Tesfasyone H, et al. Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus. Lupus. 2009;18(11):980-9. doi: 10.1177/0961203309105529
86. Greenberg SA, Pinkus JL, Pinkus GS, et al. Interferon-β/α-mediated innate immune mechanisms in dermatomyositis. Ann Neurol. 2005;57:664-78. doi: 10.1002/ana.20464
87. Eloranta ML, Rö nnblom L. Cause and consequences of the activated type I interferon system in SLE. J Mol Med (Berl). 2016;94(10):1103-10. doi: 10.1007/s00109-016-1421-4
88. Eloranta ML, Lö vgren T, Finke D, et al. Regulation of the interferon-alpha production induced by RNA-containing immune complexes in plasmacytoid dendritic cells. Arthritis Rheum. 2009;60:2418-27. doi: 10.1002/art.24686
89. Rose T, Grutzkau A, Klotsche J, et al. Are interferon-related biomarkers advantageous for monitoring disease activity in systemic lupus erythematosus? A longitudinal benchmark study. Rheumatology (Oxford). 2017;56:1618-26. doi: 10.1093/rheumatology/kex220
90. Liao AP, Salajegheh M, Nazareno R, et al. Interferon β is associated with type 1 interferon-inducible gene expression in dermatomyositis. Ann Rheum Dis. 2011;70:831-6. doi: 10.1136/ard.2010.139949
91. Weckerle CE, Franek BS, Kelly JA, et al. Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosus. Arthritis Rheum. 2011;63(4):1044-53. doi: 10.1002/art.30187
92. Berggren O, Hagberg N, Weber G, et al. B lymphocytes enhance the interferon-alpha production by plasmacytoid dendritic cells. Arthritis Rheum. 2012;64:3409-19.
93. Connelly KL, Kandane-Rathayake R, Huq M, et al. Longitudinal association of type 1 interferon-induced chemokines with disease activity in systemic lupus erythematosus. Scientific Report. 2018;8:3268. doi: 10.1038/s41598-018-20203-9
94. Somani A-K, Swick AR, Cooper KD, et al. Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling. Arch Dermatol. 2008;144:1341-9. doi: 10.1001/archderm.144.10.1341
95. doi: 10.1002/art.34599
96. Baechler EC, Batliwalla FM, Karypis G, et al. Interferoninducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A. 2003;100(5):2610-5. doi: 10.1073/pnas.0337679100
97. Banchereau R, Hong S, Cantarel B, et al. Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients. Cell. 2016;165(3):551-65. doi: 10.1016/j.cell.2016.03.008
98. Piper CJM, Wilkinson MGL, Deakin CT, et al. CD19+CD24hiCD38hi B Cells Are Expanded in Juvenile Dermatomyositis and Exhibit a Pro-Inflammatory Phenotype After Activation Through Toll-Like Receptor 7 and Interferon-α. Front Immunol. 2018;9. doi: 10.3389/fimmu.2018.01372
99. Munroe ME, Lu R, Zhao YD, et al. Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. Ann Rheum Dis. 2016;75(11):2014-21. doi: 10.1136/annrheumdis-2015-2081
100. Leonard D, Eloranta ML, Hagberg N, et al. Activated T cells enhance interferon-alpha production by plasmacytoid dendritic cells stimulated with RNA-containing immune complexes. Ann Rheum Dis. 2016;75(9):1728-34. doi: 10.1136/annrheumdis-2015-208055
101. Ghodke-Puranik Y, Niewold TB. Genetics of the type I interferon pathway in systemic lupus erythematosus. Int J Clin Rheumtol. 2013;8:657-69. doi: 10.2217/ijr.13.58
102. Oon S, Wilson NJ, Wicks I. Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway. Clin Transl Immunol. 2016;5:e79. doi: 10.1038/cti.2016.26
103. Skurkovich SV, Klinova EG, Eremkina EI, Levina NV. Immunosupressive effect of anti-interferon serum. Nature. 1974;247:551-2. doi: 10.1038/247551a0
104. Niewold TB, Hua J, Lehman TJ, et al. High serum IFN-α activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun. 2007;8:492-502. doi: 10.1038/sj.gene.6364408
105. Mathian A, Hie M, Cohen-Aubart F, et al. Targeting interferons in systemic lupus erythematosus: current and future prospects. Drugs. 2015;75:835-46. doi: 10.1007/s40265-015-0394-x
106. Langefeld CD, Ainsworth HC, Cunninghame Graham DS, et al. Transancestral mapping and genetic load in systemic lupus erythematosus. Nat Commun. 2017;8:16021. doi: 10.1038/ncomms16021
107. Kariuki SN, Franek BS, Kumar AA, et al. Trait-stratified genome-wide association study identifies novel and diverse genetic associations with serologic and cytokine phenotypes in systemic lupus erythematosus. Arthritis Res Ther. 2010;12(4):R151. doi: 10.1186/ar3101
108. Skurkovich SV, Loukina GV, Sigidin YA, Skurkovich BS. Succesful first-time use of antibodies to interferon-gamma alone and combined with antibodies to tumor necrosis factor-alfa to treat rheumatic diseasers (rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, Behcet`s syndrome). Int J Immunother. 1998;14:23-32.
109. Bodewes ILA, Gottenberg JE, van Helden-Meeuwsen CG, et al. Hydroxychloroquine treatment downregulates systemic interferon activation in primary Sjö gren's syndrome in the JOQUER randomized trial. Rheumatology (Oxford). 2019 Jun 25. doi: 10.1093/rheumatology/kez242
110. Md Yusof MY, Psarras A, El-Sherbiny YM, et al. Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status. Ann Rheum Dis. 2018;77:1432-9. doi: 10.1136/annrheumdis-2018-213386
111. Niewold TB, Kelly JA, Kariuki SN, et al. IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus. Ann Rheum Dis. 2012;71(3):463-8. doi: 10.1136/annrheumdis-2011-200463
112. Sigidin AY, Loukina GV, Skurkovich B, Skurkovich SV. Randomized double-blind trial of anti-interferob-gamma antibodies in rheumatoid arthritis. Scand J Rheumatol. 2001;30:203-7. doi: 10.1080/030097401316909530
113. Gardet A, Pellerin A, McCarl CA, et al. Effect of in vivo Hydroxychloroquine and ex vivo Anti-BDCA2 mAb Treatment on pDC IFNγ Production From Patients Affected With Cutaneous Lupus Erythematosus. Front Immunol. 2019;10:275. doi: 10.3389/fimmu.2019.00275
114. Hagberg N, Joelsson M, Leonard D, et al. The Stat4 Sle risk allele Rs7574865[T] is associated with increased Il-12-induced IFN-γ production in T cells from patients with SLE. Ann Rheum Dis. 2018;77(7):1070-7. doi: 10.1136/annrheumdis-2017-212794
115. Morimoto AM, Flesher DT, Yang J, et al. Association of endogenous anti-interferon-α autoantibodies with decreased interferonpathway and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:2407-15. doi: 10.1002/art.30399
116. Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175-87. doi: 10.1136/annrheumdis-2017-211555
117. Olsen NJ, McAloose C, Carter J, et al. Clinical and Immunologic Profiles in Incomplete Lupus Erythematosus and Improvement with Hydroxychloroquine Treatment. Autoimmune Dis. 2016:8791629. doi: 10.1155/2016/8791629
118. Landolt-Marticorena C, Bonventi G, Lubovich A, et al. Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus. Ann Rheum Dis. 2009;68(9):1440-6. doi: 10.1136/ard.2008.093146
119. Lessard CJ, Li H, Adrianto I, et al. Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjö gren's syndrome. Nat Genet. 2013;45(11):1284-92. doi: 10.1038/ng.2792
120. Yao Y, Higgs BW, Morehouse C, et al. Development of potential pharmacodynamic and diagnostic markers for anti-IFN-alpha monoclonal antibody trials in systemic lupus erythematosus. Hum Genom Proteom. 2009:Article ID 374312. doi: 10.4061/2009/37431210.4061/2009/374312
121. Eloranta ML, Lö vgren T, Finke D, et al. Regulation of the interferon-alpha production induced by RNA-containing immune complexes in plasmacytoid dendritic cells. Arthritis Rheum. 2009;60:2418-27. doi: 10.1002/art.24686
122. Angiolilli C, Marut W, van der Kroef M, et al. New insights into the genetics and epigenetics of systemic sclerosis. Nat Rev Rheumatol. 2018;14(11):657-73. doi: 10.1038/s41584-018-0099-0
123. Petri M, Singh S, Tesfasyone H, et al. Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus. Lupus. 2009;18(11):980-9. doi: 10.1177/0961203309105529
124. Merrill JT, Wallace DJ, Petri M, et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011;70:1905-13. doi: 10.1136/ard.2010.144485
125. Dieguez-Gonzalez R, Calaza M, Perez-Pampin E, et al. Association of interferon regulatory factor 5 haplotypes, similar to that found in systemic lupus erythematosus, in a large subgroup of patients with rheumatoid arthritis. Arthritis Rheum. 2008;58:1264-74. doi: 10.1002/art.23426
126. Rose T, Grutzkau A, Klotsche J, et al. Are interferon-related biomarkers advantageous for monitoring disease activity in systemic lupus erythematosus? A longitudinal benchmark study. Rheumatology (Oxford). 2017;56:1618-26. doi: 10.1093/rheumatology/kex220
127. Berggren O, Hagberg N, Weber G, et al. B lymphocytes enhance the interferon-alpha production by plasmacytoid dendritic cells. Arthritis Rheum. 2012;64:3409-19.
128. Petri M, Wallace DJ, Spindler A, et al. Sifalimumab, a human anti-interferon-alpha monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum. 2013;65:1011-21. doi: 10.1002/art.37824
129. doi: 10.1002/art.34599
130. Nordang GB, Viken MK, Amundsen SS, et al. Interferon regulatory factor 5 gene polymorphism confers risk to several rheumatic diseases and correlates with expression of alternative thymic transcripts. Rheumatology (Oxford). 2012;51(4):619-26. doi: 10.1093/rheumatology/ker364
131. Connelly KL, Kandane-Rathayake R, Huq M, et al. Longitudinal association of type 1 interferon-induced chemokines with disease activity in systemic lupus erythematosus. Scientific Report. 2018;8:3268. doi: 10.1038/s41598-018-20203-9
132. Khamashta M, Merrill JT, Werth VP, et al. Sifalimumab, an antiinterferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75:1909-16. doi: 10.1136/annrheumdis-2015-208562
133. Demirkaya E, Zhou Q, Smith CK, et al. Brief report: deficiency of complement 1r subcomponent in early-onset systemic lupus erythematosus: the role of disease-modifying alleles in a monogenic disease. Arthritis Rheum. 2017;69:1832-9. doi: 10.1002/art.40158
134. Leonard D, Eloranta ML, Hagberg N, et al. Activated T cells enhance interferon-alpha production by plasmacytoid dendritic cells stimulated with RNA-containing immune complexes. Ann Rheum Dis. 2016;75(9):1728-34. doi: 10.1136/annrheumdis-2015-208055
135. Banchereau R, Hong S, Cantarel B, et al. Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients. Cell. 2016;165(3):551-65. doi: 10.1016/j.cell.2016.03.008
136. Tcherepanova I, Curtis M, Sale M, et al. SAT0193 Results of a randomized placebo controlled phase ia study of AGS-009, a humanized anti-interferon-α monoclonal antibody in subjects with systemic lupus erythematosus. Ann Rheum Dis. 2013;71(Suppl 3):536.3-7. doi: 10.1136/annrheumdis-2012-eular.3140
137. Ghodke-Puranik Y, Dorschner JM, Vsetecka DM, et al. Lupusassociated functional polymorphism in Pnp causes cell cycle abnormalities and interferon pathway activation in human immune cells. Arthritis Rheum. 2017;69:2328-37. doi: 10.1002/art.40304
138. Ghodke-Puranik Y, Niewold TB. Genetics of the type I interferon pathway in systemic lupus erythematosus. Int J Clin Rheumtol. 2013;8:657-69. doi: 10.2217/ijr.13.58
139. Skurkovich SV, Klinova EG, Eremkina EI, Levina NV. Immunosupressive effect of anti-interferon serum. Nature. 1974;247:551-2. doi: 10.1038/247551a0
140. Kalunian KC, Merrill JT, Maciuca R, et al. A phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. 2016;75:196-202. doi: 10.1136/annrheumdis-2014-206090
141. Kariuki SN, Ghodke-Puranik Y, Dorschner JM, et al. Genetic analysis of the pathogenic molecular sub-phenotype interferonalpha identifies multiple novel loci involved in systemic lupus erythematosus. Genes Immun. 2015;16:15-23. doi: 10.1038/gene.2014.57
142. Langefeld CD, Ainsworth HC, Cunninghame Graham DS, et al. Transancestral mapping and genetic load in systemic lupus erythematosus. Nat Commun. 2017;8:16021. doi: 10.1038/ncomms16021
143. Skurkovich SV, Loukina GV, Sigidin YA, Skurkovich BS. Succesful first-time use of antibodies to interferon-gamma alone and combined with antibodies to tumor necrosis factor-alfa to treat rheumatic diseasers (rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, Behcet`s syndrome). Int J Immunother. 1998;14:23-32.
144. Peng L, Oganesyan V, Wu H, et al. Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-α receptor 1 antibody. MAbs. 2015;7:428-39. doi: 10.1080/19420862.2015.1007810
145. Niewold TB, Kelly JA, Kariuki SN, et al. IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus. Ann Rheum Dis. 2012;71(3):463-8. doi: 10.1136/annrheumdis-2011-200463
146. Faridi MH, Khan SQ, Zhao W, et al. Cd11b activation suppresses TLR-dependent inflammation and autoimmunity in systemic lupus erythematosus. J Clin Invest. 2017;127:1271-83. doi: 10.1172/JCI88442
147. Sigidin AY, Loukina GV, Skurkovich B, Skurkovich SV. Randomized double-blind trial of anti-interferob-gamma antibodies in rheumatoid arthritis. Scand J Rheumatol. 2001;30:203-7. doi: 10.1080/030097401316909530
148. Riggs JM, Hanna RN, Rajan B, et al. Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus. Lupus Sci Med. 2018;5:e000261. doi: 10.1136/lupus-2018-000261
149. Coit P, Jeffries M, Altorok N, et al. Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferon-regulated genes in naive CD4+ T cells from lupus patients. J Autoimmun. 2013;43:78-84. doi: 10.1016/j.jaut.2013.04.003
150. Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175-87. doi: 10.1136/annrheumdis-2017-211555
151. Hagberg N, Joelsson M, Leonard D, et al. The Stat4 Sle risk allele Rs7574865[T] is associated with increased Il-12-induced IFN-γ production in T cells from patients with SLE. Ann Rheum Dis. 2018;77(7):1070-7. doi: 10.1136/annrheumdis-2017-212794
152. Felten R, Scher F, Sagez F, et al. Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date. Drug Des Devel Ther. 2019;13:1535-43. doi: 10.2147/DDDT.S170969
153. Cheng J, Wu R, Long L, et al. Mirna-451a targets Ifn regulatory factor 8 for the progression of systemic lupus erythematosus. Inflammation. 2017;40:676-87. doi: 10.1007/s10753-017-0514-8
154. Lessard CJ, Li H, Adrianto I, et al. Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjö gren's syndrome. Nat Genet. 2013;45(11):1284-92. doi: 10.1038/ng.2792
155. Yao Y, Higgs BW, Morehouse C, et al. Development of potential pharmacodynamic and diagnostic markers for anti-IFN-alpha monoclonal antibody trials in systemic lupus erythematosus. Hum Genom Proteom. 2009:Article ID 374312. doi: 10.4061/2009/37431210.4061/2009/374312
156. Furie R, Khamashta M, Merrill JT, et al. Anifrolumab, an antiinterferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheum. 2017;69:376-86. doi: 10.1002/art.39962
157. Merrill JT, Wallace DJ, Petri M, et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011;70:1905-13. doi: 10.1136/ard.2010.144485
158. Smith S, Fernando T, Wu PW, et al. Microrna-302d targets Irf9 to regulate the Ifn-induced gene expression in SLE. J Autoimmun. 2017;79:105-11. doi: 10.1016/j.jaut.2017.03.003
159. Angiolilli C, Marut W, van der Kroef M, et al. New insights into the genetics and epigenetics of systemic sclerosis. Nat Rev Rheumatol. 2018;14(11):657-73. doi: 10.1038/s41584-018-0099-0
160. Merrill JT, Furie R, Werth VP, et al. Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus. Lupus Sci Med. 2018;5(1):e000284. doi: 10.1136/lupus-2018-000284
161. Petri M, Wallace DJ, Spindler A, et al. Sifalimumab, a human anti-interferon-alpha monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum. 2013;65:1011-21. doi: 10.1002/art.37824
162. Dieguez-Gonzalez R, Calaza M, Perez-Pampin E, et al. Association of interferon regulatory factor 5 haplotypes, similar to that found in systemic lupus erythematosus, in a large subgroup of patients with rheumatoid arthritis. Arthritis Rheum. 2008;58:1264-74. doi: 10.1002/art.23426
163. Van den Hoogen LL, van Roon JAG, Mertens JS, et al. Galectin-9 is an easy to measure biomarker for the interferon signature in systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis. 2018;77(12):1810-4. doi: 10.1136/annrheumdis-2018-213497
164. Casey KA, Guo X, Smith MA, et al. Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE. Lupus Sci Med. 2018;5(1):e000286. doi: 10.1136/lupus-2018-000286
165. Khamashta M, Merrill JT, Werth VP, et al. Sifalimumab, an antiinterferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75:1909-16. doi: 10.1136/annrheumdis-2015-208562
166. Nordang GB, Viken MK, Amundsen SS, et al. Interferon regulatory factor 5 gene polymorphism confers risk to several rheumatic diseases and correlates with expression of alternative thymic transcripts. Rheumatology (Oxford). 2012;51(4):619-26. doi: 10.1093/rheumatology/ker364
167. Oliveira JJ, Karrar S, Rainbow DB, et al. The plasma biomarker soluble SIGLEC-1 is associated with the type I interferon transcriptional signature, ethnic background and renal disease in systemic lupus erythematosus. Arthritis Res Ther. 2018;20(1):152. doi: 10.1186/s13075-018-1649-1
168. Goldberg A, Geppert T, Schiopu E, et al. Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study. Arthritis Res Ther. 2014;16:R57.
169. Demirkaya E, Zhou Q, Smith CK, et al. Brief report: deficiency of complement 1r subcomponent in early-onset systemic lupus erythematosus: the role of disease-modifying alleles in a monogenic disease. Arthritis Rheum. 2017;69:1832-9. doi: 10.1002/art.40158
170. Tcherepanova I, Curtis M, Sale M, et al. SAT0193 Results of a randomized placebo controlled phase ia study of AGS-009, a humanized anti-interferon-α monoclonal antibody in subjects with systemic lupus erythematosus. Ann Rheum Dis. 2013;71(Suppl 3):536.3-7. doi: 10.1136/annrheumdis-2012-eular.3140
171. Lü bbers J, Brink M, van de Stadt LA, et al. The type I IFN signature as a biomarker of preclinical rheumatoid arthritis. Ann Rheum Dis. 2013;72(5):776-80. doi: 10.1136/annrheumdis-2012-2
172. doi: 10.1186/ar4492
173. Kalunian KC, Merrill JT, Maciuca R, et al. A phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. 2016;75:196-202. doi: 10.1136/annrheumdis-2014-206090
174. Thurlings RM, Boumans M, Tekstra J, et al. Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. Arthritis Rheum. 2010;62:3607-14. doi: 10.1002/art.27702
175. Ghodke-Puranik Y, Dorschner JM, Vsetecka DM, et al. Lupusassociated functional polymorphism in Pnp causes cell cycle abnormalities and interferon pathway activation in human immune cells. Arthritis Rheum. 2017;69:2328-37. doi: 10.1002/art.40304
176. Update on TULIP 1 phase III trial for anifrolumab in systemic lupus erythematosus. Available from: https://www.astrazeneca.com/media-centre/press-releases/2018/update-on-tulip-1-phase-iii-trial-for-anifrolumab-insystemic-lupus-erythematosus-31082018.html. Accessed January 10, 2019.
177. Peng L, Oganesyan V, Wu H, et al. Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-α receptor 1 antibody. MAbs. 2015;7:428-39. doi: 10.1080/19420862.2015.1007810
178. Kariuki SN, Ghodke-Puranik Y, Dorschner JM, et al. Genetic analysis of the pathogenic molecular sub-phenotype interferonalpha identifies multiple novel loci involved in systemic lupus erythematosus. Genes Immun. 2015;16:15-23. doi: 10.1038/gene.2014.57
179. Raterman HG, Vosslamber S, De RS, et al. The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res Ther. 2012;14:R95. doi: 10.1186/ar3819
180. Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843-62. doi: 10.1038/nrd.2017.201
181. Riggs JM, Hanna RN, Rajan B, et al. Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus. Lupus Sci Med. 2018;5:e000261. doi: 10.1136/lupus-2018-000261
182. Sanayama Y, Ikeda K, Saito Y, et al. Prediction of therapeutic responses to tocilizumab in patients with rheumatoid arthritis: biomarkers identified by analysis of gene expression in peripheral blood mononuclear cells using genome-wide DNA microarray. Arthritis Rheum. 2014;66(6):1421-31. doi: 10.1002/art.38400
183. Faridi MH, Khan SQ, Zhao W, et al. Cd11b activation suppresses TLR-dependent inflammation and autoimmunity in systemic lupus erythematosus. J Clin Invest. 2017;127:1271-83. doi: 10.1172/JCI88442
184. Nasonov EL, Lila AM. Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: new opportunities and prospects. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(1):8-16 (In Russ.). doi: 10.14412/1995-4484-2019-8-16
185. Coit P, Jeffries M, Altorok N, et al. Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferon-regulated genes in naive CD4+ T cells from lupus patients. J Autoimmun. 2013;43:78-84. doi: 10.1016/j.jaut.2013.04.003
186. Mavragani CP, La DT, Stohl W, Crow MK. Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-β/α ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort. Arthritis Rheum. 2010;62:392-401. doi: 10.1002/art.27226
187. Felten R, Scher F, Sagez F, et al. Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date. Drug Des Devel Ther. 2019;13:1535-43. doi: 10.2147/DDDT.S170969
188. Mok CC. The Jakinibs in systemic lupus erythematosus: progress and prospects. Expert Opin Investig Drugs. 2019;28(1):85-92. doi: 10.1080/13543784.2019.1551358
189. Furie R, Khamashta M, Merrill JT, et al. Anifrolumab, an antiinterferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheum. 2017;69:376-86. doi: 10.1002/art.39962
190. Cheng J, Wu R, Long L, et al. Mirna-451a targets Ifn regulatory factor 8 for the progression of systemic lupus erythematosus. Inflammation. 2017;40:676-87. doi: 10.1007/s10753-017-0514-8
191. Wampler Muskardin T, Vashisht P, Dorschner JM, et al. Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritis. Ann Rheum Dis. 2016;75(10):1757-62. doi: 10.1136/annrheumdis-2015-208001
192. Sanchez GAM, Reinhardt A, Ramsey S, et al. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018;128(7):3041-52. doi: 10.1172/JCI98814
193. Merrill JT, Furie R, Werth VP, et al. Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus. Lupus Sci Med. 2018;5(1):e000284. doi: 10.1136/lupus-2018-000284
194. Smith S, Fernando T, Wu PW, et al. Microrna-302d targets Irf9 to regulate the Ifn-induced gene expression in SLE. J Autoimmun. 2017;79:105-11. doi: 10.1016/j.jaut.2017.03.003
195. De Jong TD, Blits M, de Ridder S, et al. Type I interferon response gene expression in established rheumatoid arthritis is not associated with clinical parameters. Arthritis Res Ther. 2016;18:Article number 290. doi: 10.1186/s13075-016-1191-y
196. Kö nig N, Fiehn C, Wolf C, et al. Familial chilblain lupus due to a gain-of-function mutation in STING. Ann Rheum Dis. 2017;76(2):468-72.
197. Casey KA, Guo X, Smith MA, et al. Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE. Lupus Sci Med. 2018;5(1):e000286. doi: 10.1136/lupus-2018-000286
198. Van den Hoogen LL, van Roon JAG, Mertens JS, et al. Galectin-9 is an easy to measure biomarker for the interferon signature in systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis. 2018;77(12):1810-4. doi: 10.1136/annrheumdis-2018-213497
199. De Jong TD, Vosslamber S, Blits M, et al. Effect of prednisone on type I interferon signature in rheumatoid arthritis: consequences for response prediction to rituximab. Arthritis Res Ther. 2015;17:78. doi: 10.1186/s13075-015-0564-y
200. Rodero MP, Fremond M-L, Rice GI, et al. JAK inhibition in STING-associated interferonopathy. Ann Rheum Dis. 2016;75(12):e75. doi: 10.1136/annrheumdis-2016-210504
201. Oliveira JJ, Karrar S, Rainbow DB, et al. The plasma biomarker soluble SIGLEC-1 is associated with the type I interferon transcriptional signature, ethnic background and renal disease in systemic lupus erythematosus. Arthritis Res Ther. 2018;20(1):152. doi: 10.1186/s13075-018-1649-1
202. De Jong TD, Snoek T, Mantel E, et al. Dynamics of the Type I Interferon Response During Immunosuppressive Therapy in Rheumatoid Arthritis. Front Immunol. 2019 Apr 24;10:902. doi: 10.3389/fimmu.2019.00902
203. Goldberg A, Geppert T, Schiopu E, et al. Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study. Arthritis Res Ther. 2014;16:R57.
204. Seo J, Kang J-A, Suh DI, et al. Tofacitinib relieves symptoms of stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy caused by 2 de novo variants in TMEM173. J Allergy Clin Immunol. 2017;139(4):1396-9.e12. doi: 10.1016/j.jaci.2016.10.030
205. doi: 10.1186/ar4492
206. Thorlacius GE, Wahren-Herlenius M, Ronnblom L. An update on the role of type I interferons in systemic lupus erythematosus and Sjogren's syndrome. Curr Opin Rheumatol. 2018;30:471-81. doi: 10.1097/BOR.0000000000000524
207. Lü bbers J, Brink M, van de Stadt LA, et al. The type I IFN signature as a biomarker of preclinical rheumatoid arthritis. Ann Rheum Dis. 2013;72(5):776-80. doi: 10.1136/annrheumdis-2012-2
208. Volpi S, Insalaco A, Caorsi R, et al. Efficacy and Adverse Events During Janus Kinase Inhibitor Treatment of SAVI Syndrome. J Clin Immunol. 2019 Jul;39(5):476-85. doi: 10.1007/s10875-019-00645-0
209. Nezos A, Gravani F, Tassidou A, et al. Type I and II interferon signatures in Sjogren's syndrome pathogenesis: contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis. J Autoimmun. 2015;63:47-58. doi: 10.1016/j.jaut.2015.07.002
210. Update on TULIP 1 phase III trial for anifrolumab in systemic lupus erythematosus. Available from: https://www.astrazeneca.com/media-centre/press-releases/2018/update-on-tulip-1-phase-iii-trial-for-anifrolumab-insystemic-lupus-erythematosus-31082018.html. Accessed January 10, 2019.
211. Thurlings RM, Boumans M, Tekstra J, et al. Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. Arthritis Rheum. 2010;62:3607-14. doi: 10.1002/art.27702
212. Ikeda K, Hayakawa K, Fujishiro M, et al. JAK inhibitor has the amelioration effect in lupus-prone mice: the involvement of IFN signature gene downregulation. BMC Immunol. 2017;18(1):41. doi: 10.1186/s12865-017-0225-9
213. Benchabane S, Belkhelfa M, Belguendouz H, et al. Interferon-γ inhibits inflammatory responses mediators via suppression of iNOS signaling pathway in PBMCs from patients with primary Sjö gren's syndrome. Inflammopharmacology. 2018;26:1165-74. doi: 10.1007/s10787-018-0499-4
214. Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843-62. doi: 10.1038/nrd.2017.201
215. Raterman HG, Vosslamber S, De RS, et al. The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res Ther. 2012;14:R95. doi: 10.1186/ar3819
216. Furumoto Y, Smith CK, Blanco L, et al. Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction. Arthritis Rheum. 2017;69(1):148-60. doi: 10.1002/art.39818
217. Bodewes ILA, Al-Ali S, van Helden-Meeuwsen CG, et al. Systemic interferon type I and type II signatures in primary Sjö gren's syndrome reveal differences in biological disease activity. Rheumatology. 2018;57:921-30. doi: 10.1093/rheumatology/kex490
218. Sanayama Y, Ikeda K, Saito Y, et al. Prediction of therapeutic responses to tocilizumab in patients with rheumatoid arthritis: biomarkers identified by analysis of gene expression in peripheral blood mononuclear cells using genome-wide DNA microarray. Arthritis Rheum. 2014;66(6):1421-31. doi: 10.1002/art.38400
219. Nasonov EL, Lila AM. Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: new opportunities and prospects. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(1):8-16 (In Russ.). doi: 10.14412/1995-4484-2019-8-16
220. Yamamoto M, Yokoyama Y, Shimizu Y, et al. Tofacitinib can decrease anti-DNA antibody titers in inactive systemic lupus erythematosus complicated by rheumatoid arthritis. Mod Rheumatol. 2016;26(4):633-4. doi: 10.3109/14397595.2015.1069473
221. Dieude P, Guedj M, Wipff J, et al. STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis. Arthritis Rheum. 2009;60:2472-9. doi: 10.1002/art.24688
222. Mok CC. The Jakinibs in systemic lupus erythematosus: progress and prospects. Expert Opin Investig Drugs. 2019;28(1):85-92. doi: 10.1080/13543784.2019.1551358
223. Mavragani CP, La DT, Stohl W, Crow MK. Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-β/α ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort. Arthritis Rheum. 2010;62:392-401. doi: 10.1002/art.27226
224. You H, Zhang G, Wang Q, et al. Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre. Ann Rheum Dis. 2019 Apr 20. doi: 10.1136/annrheumdis-2019-215455
225. Sanchez GAM, Reinhardt A, Ramsey S, et al. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018;128(7):3041-52. doi: 10.1172/JCI98814
226. Gourh P, Agarwal SK, Divecha D, et al. Polymorphisms in TBX21 and STAT4 increase the risk of systemic sclerosis: evidence of possible gene-gene interaction and alterations in Th1/Th2 cytokines. Arthritis Rheum. 2009;60:3794-806. doi: 10.1002/art.24958
227. Wampler Muskardin T, Vashisht P, Dorschner JM, et al. Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritis. Ann Rheum Dis. 2016;75(10):1757-62. doi: 10.1136/annrheumdis-2015-208001
228. Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10143):222-31. doi: 10.1016/S0140-6736(18)31363-1
229. Rueda B, Broen J, Simeon C, et al. The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype. Hum Mol Genet. 2009;18:2071-7. doi: 10.1093/hmg/ddp119
230. De Jong TD, Blits M, de Ridder S, et al. Type I interferon response gene expression in established rheumatoid arthritis is not associated with clinical parameters. Arthritis Res Ther. 2016;18:Article number 290. doi: 10.1186/s13075-016-1191-y
231. Kö nig N, Fiehn C, Wolf C, et al. Familial chilblain lupus due to a gain-of-function mutation in STING. Ann Rheum Dis. 2017;76(2):468-72.
232. Zhang LJ. Type 1 Interferons Potential Initiating Factors Linking Skin Wounds With Psoriasis Pathogenesis. Front Immunol. 2019;10:1440. doi: 10.3389/fimmu.2019.01440
233. Rodero MP, Fremond M-L, Rice GI, et al. JAK inhibition in STING-associated interferonopathy. Ann Rheum Dis. 2016;75(12):e75. doi: 10.1136/annrheumdis-2016-210504
234. De Jong TD, Vosslamber S, Blits M, et al. Effect of prednisone on type I interferon signature in rheumatoid arthritis: consequences for response prediction to rituximab. Arthritis Res Ther. 2015;17:78. doi: 10.1186/s13075-015-0564-y
235. Skaug B, Assassi S. Type I interferon dysregulation in Systemic Sclerosis. Cytokine. 2019 Jan 23. doi: 10.1016/j.cyto.2018.12.018
236. Mylonas A, Conrad C. Psoriasis: Classical vs. Paradoxical. The Yin-Yang of TNF and Type I Interferon. Front Immunol. 2018;9:2746. doi: 10.3389/fimmu.2018.02746
237. Christmann RB, Sampaio-Barros P, Stifano G, et al. Association of interferon- and transforming growth factor β-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis. Arthritis Rheum. 2014;66:714-25. doi: 10.1002/art.38288
238. Seo J, Kang J-A, Suh DI, et al. Tofacitinib relieves symptoms of stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy caused by 2 de novo variants in TMEM173. J Allergy Clin Immunol. 2017;139(4):1396-9.e12. doi: 10.1016/j.jaci.2016.10.030
239. De Jong TD, Snoek T, Mantel E, et al. Dynamics of the Type I Interferon Response During Immunosuppressive Therapy in Rheumatoid Arthritis. Front Immunol. 2019 Apr 24;10:902. doi: 10.3389/fimmu.2019.00902
240. Robinson ES, Werth VP. The role of cytokines in the pathogenesis of cutaneous lupus erythematosus. Cytokine. 2015;73:326-34. doi: 10.1016/j.cyto.2015.01.031
241. George PM, Oliver E, Dorfmuller P, et al. Evidence for the involvement of type I interferon in pulmonary arterial hypertension. Circ Res. 2014;114:677-88. doi: 10.1161/CIRCRESAHA.114.302221
242. Thorlacius GE, Wahren-Herlenius M, Ronnblom L. An update on the role of type I interferons in systemic lupus erythematosus and Sjogren's syndrome. Curr Opin Rheumatol. 2018;30:471-81. doi: 10.1097/BOR.0000000000000524
243. Volpi S, Insalaco A, Caorsi R, et al. Efficacy and Adverse Events During Janus Kinase Inhibitor Treatment of SAVI Syndrome. J Clin Immunol. 2019 Jul;39(5):476-85. doi: 10.1007/s10875-019-00645-0
244. Rubin RL. Drug-induced lupus. Expert Opin Drug Safe. 2015;14:361-78. doi: 10.1517/14740338.2015.995089
245. Brkic Z, van Bon L, Cossu M, et al. The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis. Ann Rheum Dis. 2016;75(8):1567-73. doi: 10.1136/annrheumdis-2015-207
246. Nezos A, Gravani F, Tassidou A, et al. Type I and II interferon signatures in Sjogren's syndrome pathogenesis: contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis. J Autoimmun. 2015;63:47-58. doi: 10.1016/j.jaut.2015.07.002
247. Ikeda K, Hayakawa K, Fujishiro M, et al. JAK inhibitor has the amelioration effect in lupus-prone mice: the involvement of IFN signature gene downregulation. BMC Immunol. 2017;18(1):41. doi: 10.1186/s12865-017-0225-9
248. Ciechanowicz P, Rakowska A, Sikora M, Rudnicka L. JAKinhibitors in dermatology. Current evidence and future applications. J Dermatolog Treat. 2018 Nov;15:1-22. doi: 10.1080/09546634.2018.1546043
249. Van den Hoogen LL, Fritsch-Stork RD, Versnel MA, et al. Monocyte type I interferon signature in antiphospholipid syndrome is related to proinflammatory monocyte subsets, hydroxychloroquine and statin use. Ann Rheum Dis. 2016;75:e81. doi: 10.1136/annrheumdis-2016-210485
250. Benchabane S, Belkhelfa M, Belguendouz H, et al. Interferon-γ inhibits inflammatory responses mediators via suppression of iNOS signaling pathway in PBMCs from patients with primary Sjö gren's syndrome. Inflammopharmacology. 2018;26:1165-74. doi: 10.1007/s10787-018-0499-4
251. Furumoto Y, Smith CK, Blanco L, et al. Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction. Arthritis Rheum. 2017;69(1):148-60. doi: 10.1002/art.39818
252. Bodewes ILA, Al-Ali S, van Helden-Meeuwsen CG, et al. Systemic interferon type I and type II signatures in primary Sjö gren's syndrome reveal differences in biological disease activity. Rheumatology. 2018;57:921-30. doi: 10.1093/rheumatology/kex490
253. Ugolini-Lopes MR, Torrezan GT, Gandara APR, et al. Enhanced type I interferon gene signature in primary antiphospholipid syndrome: Association with earlier disease onset and preeclampsia. Autoimmun Rev. 2019;18(4):393-8. doi: 10.1016/j.autrev.2018.11.004
254. Yamamoto M, Yokoyama Y, Shimizu Y, et al. Tofacitinib can decrease anti-DNA antibody titers in inactive systemic lupus erythematosus complicated by rheumatoid arthritis. Mod Rheumatol. 2016;26(4):633-4. doi: 10.3109/14397595.2015.1069473
255. Dieude P, Guedj M, Wipff J, et al. STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis. Arthritis Rheum. 2009;60:2472-9. doi: 10.1002/art.24688
256. You H, Zhang G, Wang Q, et al. Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre. Ann Rheum Dis. 2019 Apr 20. doi: 10.1136/annrheumdis-2019-215455
257. Palli E, Kravvariti E, Tektonidou MG. Type I Interferon Signature in Primary Antiphospholipid Syndrome: Clinical and Laboratory Associations. Front Immunol. 2019;10:487. doi: 10.3389/fimmu.2019.00487
258. Gourh P, Agarwal SK, Divecha D, et al. Polymorphisms in TBX21 and STAT4 increase the risk of systemic sclerosis: evidence of possible gene-gene interaction and alterations in Th1/Th2 cytokines. Arthritis Rheum. 2009;60:3794-806. doi: 10.1002/art.24958
259. Grenn RC, Yalavarthi S, Gandhi AA, et al. Endothelial progenitor dysfunction associates with a type I interferon signature in primary antiphospholipid syndrome. Ann Rheum Dis. 2017;76:450-7. doi: 10.1136/annrheumdis-2016-209442
260. Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10143):222-31. doi: 10.1016/S0140-6736(18)31363-1
261. Rueda B, Broen J, Simeon C, et al. The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype. Hum Mol Genet. 2009;18:2071-7. doi: 10.1093/hmg/ddp119
262. Greenberg SA, Pinkus JL, Pinkus GS, et al. Interferon-β/α-mediated innate immune mechanisms in dermatomyositis. Ann Neurol. 2005;57:664-78. doi: 10.1002/ana.20464
263. Zhang LJ. Type 1 Interferons Potential Initiating Factors Linking Skin Wounds With Psoriasis Pathogenesis. Front Immunol. 2019;10:1440. doi: 10.3389/fimmu.2019.01440
264. Skaug B, Assassi S. Type I interferon dysregulation in Systemic Sclerosis. Cytokine. 2019 Jan 23. doi: 10.1016/j.cyto.2018.12.018
265. Mylonas A, Conrad C. Psoriasis: Classical vs. Paradoxical. The Yin-Yang of TNF and Type I Interferon. Front Immunol. 2018;9:2746. doi: 10.3389/fimmu.2018.02746
266. Liao AP, Salajegheh M, Nazareno R, et al. Interferon β is associated with type 1 interferon-inducible gene expression in dermatomyositis. Ann Rheum Dis. 2011;70:831-6. doi: 10.1136/ard.2010.139949
267. Christmann RB, Sampaio-Barros P, Stifano G, et al. Association of interferon- and transforming growth factor β-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis. Arthritis Rheum. 2014;66:714-25. doi: 10.1002/art.38288
268. Robinson ES, Werth VP. The role of cytokines in the pathogenesis of cutaneous lupus erythematosus. Cytokine. 2015;73:326-34. doi: 10.1016/j.cyto.2015.01.031
269. Somani A-K, Swick AR, Cooper KD, et al. Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling. Arch Dermatol. 2008;144:1341-9. doi: 10.1001/archderm.144.10.1341
270. George PM, Oliver E, Dorfmuller P, et al. Evidence for the involvement of type I interferon in pulmonary arterial hypertension. Circ Res. 2014;114:677-88. doi: 10.1161/CIRCRESAHA.114.302221
271. Piper CJM, Wilkinson MGL, Deakin CT, et al. CD19+CD24hiCD38hi B Cells Are Expanded in Juvenile Dermatomyositis and Exhibit a Pro-Inflammatory Phenotype After Activation Through Toll-Like Receptor 7 and Interferon-α. Front Immunol. 2018;9. doi: 10.3389/fimmu.2018.01372
272. Rubin RL. Drug-induced lupus. Expert Opin Drug Safe. 2015;14:361-78. doi: 10.1517/14740338.2015.995089
273. Brkic Z, van Bon L, Cossu M, et al. The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis. Ann Rheum Dis. 2016;75(8):1567-73. doi: 10.1136/annrheumdis-2015-207
274. Oon S, Wilson NJ, Wicks I. Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway. Clin Transl Immunol. 2016;5:e79. doi: 10.1038/cti.2016.26
275. Ciechanowicz P, Rakowska A, Sikora M, Rudnicka L. JAKinhibitors in dermatology. Current evidence and future applications. J Dermatolog Treat. 2018 Nov;15:1-22. doi: 10.1080/09546634.2018.1546043
276. Van den Hoogen LL, Fritsch-Stork RD, Versnel MA, et al. Monocyte type I interferon signature in antiphospholipid syndrome is related to proinflammatory monocyte subsets, hydroxychloroquine and statin use. Ann Rheum Dis. 2016;75:e81. doi: 10.1136/annrheumdis-2016-210485
277. Mathian A, Hie M, Cohen-Aubart F, et al. Targeting interferons in systemic lupus erythematosus: current and future prospects. Drugs. 2015;75:835-46. doi: 10.1007/s40265-015-0394-x
278. Ugolini-Lopes MR, Torrezan GT, Gandara APR, et al. Enhanced type I interferon gene signature in primary antiphospholipid syndrome: Association with earlier disease onset and preeclampsia. Autoimmun Rev. 2019;18(4):393-8. doi: 10.1016/j.autrev.2018.11.004
279. Bodewes ILA, Gottenberg JE, van Helden-Meeuwsen CG, et al. Hydroxychloroquine treatment downregulates systemic interferon activation in primary Sjö gren's syndrome in the JOQUER randomized trial. Rheumatology (Oxford). 2019 Jun 25. doi: 10.1093/rheumatology/kez242
280. Palli E, Kravvariti E, Tektonidou MG. Type I Interferon Signature in Primary Antiphospholipid Syndrome: Clinical and Laboratory Associations. Front Immunol. 2019;10:487. doi: 10.3389/fimmu.2019.00487
281. Gardet A, Pellerin A, McCarl CA, et al. Effect of in vivo Hydroxychloroquine and ex vivo Anti-BDCA2 mAb Treatment on pDC IFNγ Production From Patients Affected With Cutaneous Lupus Erythematosus. Front Immunol. 2019;10:275. doi: 10.3389/fimmu.2019.00275
282. Grenn RC, Yalavarthi S, Gandhi AA, et al. Endothelial progenitor dysfunction associates with a type I interferon signature in primary antiphospholipid syndrome. Ann Rheum Dis. 2017;76:450-7. doi: 10.1136/annrheumdis-2016-209442
283. Olsen NJ, McAloose C, Carter J, et al. Clinical and Immunologic Profiles in Incomplete Lupus Erythematosus and Improvement with Hydroxychloroquine Treatment. Autoimmune Dis. 2016:8791629. doi: 10.1155/2016/8791629
284. Greenberg SA, Pinkus JL, Pinkus GS, et al. Interferon-β/α-mediated innate immune mechanisms in dermatomyositis. Ann Neurol. 2005;57:664-78. doi: 10.1002/ana.20464
285. Eloranta ML, Lö vgren T, Finke D, et al. Regulation of the interferon-alpha production induced by RNA-containing immune complexes in plasmacytoid dendritic cells. Arthritis Rheum. 2009;60:2418-27. doi: 10.1002/art.24686
286. Liao AP, Salajegheh M, Nazareno R, et al. Interferon β is associated with type 1 interferon-inducible gene expression in dermatomyositis. Ann Rheum Dis. 2011;70:831-6. doi: 10.1136/ard.2010.139949
287. Berggren O, Hagberg N, Weber G, et al. B lymphocytes enhance the interferon-alpha production by plasmacytoid dendritic cells. Arthritis Rheum. 2012;64:3409-19.
288. Somani A-K, Swick AR, Cooper KD, et al. Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling. Arch Dermatol. 2008;144:1341-9. doi: 10.1001/archderm.144.10.1341
289. doi: 10.1002/art.34599
290. Piper CJM, Wilkinson MGL, Deakin CT, et al. CD19+CD24hiCD38hi B Cells Are Expanded in Juvenile Dermatomyositis and Exhibit a Pro-Inflammatory Phenotype After Activation Through Toll-Like Receptor 7 and Interferon-α. Front Immunol. 2018;9. doi: 10.3389/fimmu.2018.01372
291. Leonard D, Eloranta ML, Hagberg N, et al. Activated T cells enhance interferon-alpha production by plasmacytoid dendritic cells stimulated with RNA-containing immune complexes. Ann Rheum Dis. 2016;75(9):1728-34. doi: 10.1136/annrheumdis-2015-208055
292. Oon S, Wilson NJ, Wicks I. Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway. Clin Transl Immunol. 2016;5:e79. doi: 10.1038/cti.2016.26
293. Skurkovich SV, Klinova EG, Eremkina EI, Levina NV. Immunosupressive effect of anti-interferon serum. Nature. 1974;247:551-2. doi: 10.1038/247551a0
294. Mathian A, Hie M, Cohen-Aubart F, et al. Targeting interferons in systemic lupus erythematosus: current and future prospects. Drugs. 2015;75:835-46. doi: 10.1007/s40265-015-0394-x
295. Skurkovich SV, Loukina GV, Sigidin YA, Skurkovich BS. Succesful first-time use of antibodies to interferon-gamma alone and combined with antibodies to tumor necrosis factor-alfa to treat rheumatic diseasers (rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, Behcet`s syndrome). Int J Immunother. 1998;14:23-32.
296. Bodewes ILA, Gottenberg JE, van Helden-Meeuwsen CG, et al. Hydroxychloroquine treatment downregulates systemic interferon activation in primary Sjö gren's syndrome in the JOQUER randomized trial. Rheumatology (Oxford). 2019 Jun 25. doi: 10.1093/rheumatology/kez242
297. Sigidin AY, Loukina GV, Skurkovich B, Skurkovich SV. Randomized double-blind trial of anti-interferob-gamma antibodies in rheumatoid arthritis. Scand J Rheumatol. 2001;30:203-7. doi: 10.1080/030097401316909530
298. Gardet A, Pellerin A, McCarl CA, et al. Effect of in vivo Hydroxychloroquine and ex vivo Anti-BDCA2 mAb Treatment on pDC IFNγ Production From Patients Affected With Cutaneous Lupus Erythematosus. Front Immunol. 2019;10:275. doi: 10.3389/fimmu.2019.00275
299. Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175-87. doi: 10.1136/annrheumdis-2017-211555
300. Olsen NJ, McAloose C, Carter J, et al. Clinical and Immunologic Profiles in Incomplete Lupus Erythematosus and Improvement with Hydroxychloroquine Treatment. Autoimmune Dis. 2016:8791629. doi: 10.1155/2016/8791629
301. Yao Y, Higgs BW, Morehouse C, et al. Development of potential pharmacodynamic and diagnostic markers for anti-IFN-alpha monoclonal antibody trials in systemic lupus erythematosus. Hum Genom Proteom. 2009:Article ID 374312. doi: 10.4061/2009/37431210.4061/2009/374312
302. Eloranta ML, Lö vgren T, Finke D, et al. Regulation of the interferon-alpha production induced by RNA-containing immune complexes in plasmacytoid dendritic cells. Arthritis Rheum. 2009;60:2418-27. doi: 10.1002/art.24686
303. Merrill JT, Wallace DJ, Petri M, et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011;70:1905-13. doi: 10.1136/ard.2010.144485
304. Berggren O, Hagberg N, Weber G, et al. B lymphocytes enhance the interferon-alpha production by plasmacytoid dendritic cells. Arthritis Rheum. 2012;64:3409-19.
305. Petri M, Wallace DJ, Spindler A, et al. Sifalimumab, a human anti-interferon-alpha monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum. 2013;65:1011-21. doi: 10.1002/art.37824
306. doi: 10.1002/art.34599
307. Khamashta M, Merrill JT, Werth VP, et al. Sifalimumab, an antiinterferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75:1909-16. doi: 10.1136/annrheumdis-2015-208562
308. Leonard D, Eloranta ML, Hagberg N, et al. Activated T cells enhance interferon-alpha production by plasmacytoid dendritic cells stimulated with RNA-containing immune complexes. Ann Rheum Dis. 2016;75(9):1728-34. doi: 10.1136/annrheumdis-2015-208055
309. Tcherepanova I, Curtis M, Sale M, et al. SAT0193 Results of a randomized placebo controlled phase ia study of AGS-009, a humanized anti-interferon-α monoclonal antibody in subjects with systemic lupus erythematosus. Ann Rheum Dis. 2013;71(Suppl 3):536.3-7. doi: 10.1136/annrheumdis-2012-eular.3140
310. Skurkovich SV, Klinova EG, Eremkina EI, Levina NV. Immunosupressive effect of anti-interferon serum. Nature. 1974;247:551-2. doi: 10.1038/247551a0
311. Kalunian KC, Merrill JT, Maciuca R, et al. A phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. 2016;75:196-202. doi: 10.1136/annrheumdis-2014-206090
312. Skurkovich SV, Loukina GV, Sigidin YA, Skurkovich BS. Succesful first-time use of antibodies to interferon-gamma alone and combined with antibodies to tumor necrosis factor-alfa to treat rheumatic diseasers (rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, Behcet`s syndrome). Int J Immunother. 1998;14:23-32.
313. Peng L, Oganesyan V, Wu H, et al. Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-α receptor 1 antibody. MAbs. 2015;7:428-39. doi: 10.1080/19420862.2015.1007810
314. Sigidin AY, Loukina GV, Skurkovich B, Skurkovich SV. Randomized double-blind trial of anti-interferob-gamma antibodies in rheumatoid arthritis. Scand J Rheumatol. 2001;30:203-7. doi: 10.1080/030097401316909530
315. Riggs JM, Hanna RN, Rajan B, et al. Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus. Lupus Sci Med. 2018;5:e000261. doi: 10.1136/lupus-2018-000261
316. Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175-87. doi: 10.1136/annrheumdis-2017-211555
317. Felten R, Scher F, Sagez F, et al. Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date. Drug Des Devel Ther. 2019;13:1535-43. doi: 10.2147/DDDT.S170969
318. Yao Y, Higgs BW, Morehouse C, et al. Development of potential pharmacodynamic and diagnostic markers for anti-IFN-alpha monoclonal antibody trials in systemic lupus erythematosus. Hum Genom Proteom. 2009:Article ID 374312. doi: 10.4061/2009/37431210.4061/2009/374312
319. Furie R, Khamashta M, Merrill JT, et al. Anifrolumab, an antiinterferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheum. 2017;69:376-86. doi: 10.1002/art.39962
320. Merrill JT, Wallace DJ, Petri M, et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011;70:1905-13. doi: 10.1136/ard.2010.144485
321. Merrill JT, Furie R, Werth VP, et al. Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus. Lupus Sci Med. 2018;5(1):e000284. doi: 10.1136/lupus-2018-000284
322. Petri M, Wallace DJ, Spindler A, et al. Sifalimumab, a human anti-interferon-alpha monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum. 2013;65:1011-21. doi: 10.1002/art.37824
323. Casey KA, Guo X, Smith MA, et al. Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE. Lupus Sci Med. 2018;5(1):e000286. doi: 10.1136/lupus-2018-000286
324. Khamashta M, Merrill JT, Werth VP, et al. Sifalimumab, an antiinterferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75:1909-16. doi: 10.1136/annrheumdis-2015-208562
325. Goldberg A, Geppert T, Schiopu E, et al. Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study. Arthritis Res Ther. 2014;16:R57.
326. Tcherepanova I, Curtis M, Sale M, et al. SAT0193 Results of a randomized placebo controlled phase ia study of AGS-009, a humanized anti-interferon-α monoclonal antibody in subjects with systemic lupus erythematosus. Ann Rheum Dis. 2013;71(Suppl 3):536.3-7. doi: 10.1136/annrheumdis-2012-eular.3140
327. doi: 10.1186/ar4492
328. Kalunian KC, Merrill JT, Maciuca R, et al. A phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. 2016;75:196-202. doi: 10.1136/annrheumdis-2014-206090
329. Update on TULIP 1 phase III trial for anifrolumab in systemic lupus erythematosus. Available from: https://www.astrazeneca.com/media-centre/press-releases/2018/update-on-tulip-1-phase-iii-trial-for-anifrolumab-insystemic-lupus-erythematosus-31082018.html. Accessed January 10, 2019.
330. Peng L, Oganesyan V, Wu H, et al. Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-α receptor 1 antibody. MAbs. 2015;7:428-39. doi: 10.1080/19420862.2015.1007810
331. Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843-62. doi: 10.1038/nrd.2017.201
332. Riggs JM, Hanna RN, Rajan B, et al. Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus. Lupus Sci Med. 2018;5:e000261. doi: 10.1136/lupus-2018-000261
333. Nasonov EL, Lila AM. Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: new opportunities and prospects. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(1):8-16 (In Russ.). doi: 10.14412/1995-4484-2019-8-16
334. Felten R, Scher F, Sagez F, et al. Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date. Drug Des Devel Ther. 2019;13:1535-43. doi: 10.2147/DDDT.S170969
335. Mok CC. The Jakinibs in systemic lupus erythematosus: progress and prospects. Expert Opin Investig Drugs. 2019;28(1):85-92. doi: 10.1080/13543784.2019.1551358
336. Furie R, Khamashta M, Merrill JT, et al. Anifrolumab, an antiinterferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheum. 2017;69:376-86. doi: 10.1002/art.39962
337. Sanchez GAM, Reinhardt A, Ramsey S, et al. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018;128(7):3041-52. doi: 10.1172/JCI98814
338. Merrill JT, Furie R, Werth VP, et al. Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus. Lupus Sci Med. 2018;5(1):e000284. doi: 10.1136/lupus-2018-000284
339. Kö nig N, Fiehn C, Wolf C, et al. Familial chilblain lupus due to a gain-of-function mutation in STING. Ann Rheum Dis. 2017;76(2):468-72.
340. Casey KA, Guo X, Smith MA, et al. Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE. Lupus Sci Med. 2018;5(1):e000286. doi: 10.1136/lupus-2018-000286
341. Rodero MP, Fremond M-L, Rice GI, et al. JAK inhibition in STING-associated interferonopathy. Ann Rheum Dis. 2016;75(12):e75. doi: 10.1136/annrheumdis-2016-210504
342. Goldberg A, Geppert T, Schiopu E, et al. Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study. Arthritis Res Ther. 2014;16:R57.
343. Seo J, Kang J-A, Suh DI, et al. Tofacitinib relieves symptoms of stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy caused by 2 de novo variants in TMEM173. J Allergy Clin Immunol. 2017;139(4):1396-9.e12. doi: 10.1016/j.jaci.2016.10.030
344. doi: 10.1186/ar4492
345. Volpi S, Insalaco A, Caorsi R, et al. Efficacy and Adverse Events During Janus Kinase Inhibitor Treatment of SAVI Syndrome. J Clin Immunol. 2019 Jul;39(5):476-85. doi: 10.1007/s10875-019-00645-0
346. Update on TULIP 1 phase III trial for anifrolumab in systemic lupus erythematosus. Available from: https://www.astrazeneca.com/media-centre/press-releases/2018/update-on-tulip-1-phase-iii-trial-for-anifrolumab-insystemic-lupus-erythematosus-31082018.html. Accessed January 10, 2019.
347. Ikeda K, Hayakawa K, Fujishiro M, et al. JAK inhibitor has the amelioration effect in lupus-prone mice: the involvement of IFN signature gene downregulation. BMC Immunol. 2017;18(1):41. doi: 10.1186/s12865-017-0225-9
348. Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843-62. doi: 10.1038/nrd.2017.201
349. Furumoto Y, Smith CK, Blanco L, et al. Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction. Arthritis Rheum. 2017;69(1):148-60. doi: 10.1002/art.39818
350. Nasonov EL, Lila AM. Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: new opportunities and prospects. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(1):8-16 (In Russ.). doi: 10.14412/1995-4484-2019-8-16
351. Yamamoto M, Yokoyama Y, Shimizu Y, et al. Tofacitinib can decrease anti-DNA antibody titers in inactive systemic lupus erythematosus complicated by rheumatoid arthritis. Mod Rheumatol. 2016;26(4):633-4. doi: 10.3109/14397595.2015.1069473
352. Mok CC. The Jakinibs in systemic lupus erythematosus: progress and prospects. Expert Opin Investig Drugs. 2019;28(1):85-92. doi: 10.1080/13543784.2019.1551358
353. You H, Zhang G, Wang Q, et al. Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre. Ann Rheum Dis. 2019 Apr 20. doi: 10.1136/annrheumdis-2019-215455
354. Sanchez GAM, Reinhardt A, Ramsey S, et al. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018;128(7):3041-52. doi: 10.1172/JCI98814
355. Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10143):222-31. doi: 10.1016/S0140-6736(18)31363-1
356. Kö nig N, Fiehn C, Wolf C, et al. Familial chilblain lupus due to a gain-of-function mutation in STING. Ann Rheum Dis. 2017;76(2):468-72.
357. Zhang LJ. Type 1 Interferons Potential Initiating Factors Linking Skin Wounds With Psoriasis Pathogenesis. Front Immunol. 2019;10:1440. doi: 10.3389/fimmu.2019.01440
358. Rodero MP, Fremond M-L, Rice GI, et al. JAK inhibition in STING-associated interferonopathy. Ann Rheum Dis. 2016;75(12):e75. doi: 10.1136/annrheumdis-2016-210504
359. Mylonas A, Conrad C. Psoriasis: Classical vs. Paradoxical. The Yin-Yang of TNF and Type I Interferon. Front Immunol. 2018;9:2746. doi: 10.3389/fimmu.2018.02746
360. Seo J, Kang J-A, Suh DI, et al. Tofacitinib relieves symptoms of stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy caused by 2 de novo variants in TMEM173. J Allergy Clin Immunol. 2017;139(4):1396-9.e12. doi: 10.1016/j.jaci.2016.10.030
361. Robinson ES, Werth VP. The role of cytokines in the pathogenesis of cutaneous lupus erythematosus. Cytokine. 2015;73:326-34. doi: 10.1016/j.cyto.2015.01.031
362. Volpi S, Insalaco A, Caorsi R, et al. Efficacy and Adverse Events During Janus Kinase Inhibitor Treatment of SAVI Syndrome. J Clin Immunol. 2019 Jul;39(5):476-85. doi: 10.1007/s10875-019-00645-0
363. Rubin RL. Drug-induced lupus. Expert Opin Drug Safe. 2015;14:361-78. doi: 10.1517/14740338.2015.995089
364. Ikeda K, Hayakawa K, Fujishiro M, et al. JAK inhibitor has the amelioration effect in lupus-prone mice: the involvement of IFN signature gene downregulation. BMC Immunol. 2017;18(1):41. doi: 10.1186/s12865-017-0225-9
365. Ciechanowicz P, Rakowska A, Sikora M, Rudnicka L. JAKinhibitors in dermatology. Current evidence and future applications. J Dermatolog Treat. 2018 Nov;15:1-22. doi: 10.1080/09546634.2018.1546043
366. Furumoto Y, Smith CK, Blanco L, et al. Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction. Arthritis Rheum. 2017;69(1):148-60. doi: 10.1002/art.39818
367. Yamamoto M, Yokoyama Y, Shimizu Y, et al. Tofacitinib can decrease anti-DNA antibody titers in inactive systemic lupus erythematosus complicated by rheumatoid arthritis. Mod Rheumatol. 2016;26(4):633-4. doi: 10.3109/14397595.2015.1069473
368. You H, Zhang G, Wang Q, et al. Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre. Ann Rheum Dis. 2019 Apr 20. doi: 10.1136/annrheumdis-2019-215455
369. Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10143):222-31. doi: 10.1016/S0140-6736(18)31363-1
370. Zhang LJ. Type 1 Interferons Potential Initiating Factors Linking Skin Wounds With Psoriasis Pathogenesis. Front Immunol. 2019;10:1440. doi: 10.3389/fimmu.2019.01440
371. Mylonas A, Conrad C. Psoriasis: Classical vs. Paradoxical. The Yin-Yang of TNF and Type I Interferon. Front Immunol. 2018;9:2746. doi: 10.3389/fimmu.2018.02746
372. Robinson ES, Werth VP. The role of cytokines in the pathogenesis of cutaneous lupus erythematosus. Cytokine. 2015;73:326-34. doi: 10.1016/j.cyto.2015.01.031
373. Rubin RL. Drug-induced lupus. Expert Opin Drug Safe. 2015;14:361-78. doi: 10.1517/14740338.2015.995089
374. Ciechanowicz P, Rakowska A, Sikora M, Rudnicka L. JAKinhibitors in dermatology. Current evidence and future applications. J Dermatolog Treat. 2018 Nov;15:1-22. doi: 10.1080/09546634.2018.1546043
Review
For citations:
Nasonov E.L., Avdeeva A.S. IMMUNOINFLAMMATORY RHEUMATIC DISEASES ASSOCIATED WITH TYPE I INTERFERON: NEW EVIDENCE. Rheumatology Science and Practice. 2019;57(4):452-461. (In Russ.) https://doi.org/10.14412/1995-4484-2019-452-461
Views:
3121
Email this article 